CD8+ anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: Loss of CASA is associated with loss of viremia

Journal of Infectious Diseases

Volumn 180, Issue 1, 1999, Pages 68-75

  Wilkinson, John ^a   Zaunders, John J ^a   Carr, Andrew ^a   Cooper, David A ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; STAVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION; VIREMIA;

ANTI-HIV AGENTS; ANTIGENS, CD8; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; IMMUNITY, CELLULAR; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 0033051031     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314833     Document Type: Article

References (30)

1. Blatt SP, Hendrix CW, Butzin CA. Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patients. Ann Intern Med 1993;119:177-84.
2. Markowitz M, Hansen NI, Wilcosky TC. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 1993; 119:185-93.
3. + lymphocyte responses to antiretroviral therapy of HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:320-6.
4. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-9.
5. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
6. Autran B, Plata F, Debre P. MHC-restricted cytotoxicity against HIV. J Acquir Immune Defic Syndr 1991;4:361-7.
7. Gotch F, Rowland-Jones S, Nixon D. Longitudinal study of HIV-gag-specific cytotoxic lymphocyte responses over time in several patients. In: Racz P, Letvin N, Gluckman J, eds. Cytotoxic T-cells in HIV and other retroviral infections. Basel, Switzerland: Karger, 1992;60-5.
8. + cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 1991;87: 1462-6.
9. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;234: 1563-6.
10. Hoffman AD, Banapour B, Levy JA. Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology 1985;147:326-35.
11. Hickie C, Hickie I, Silove D, Wakefield D, Lloyd A. Delayed-type hypersensitivity skin testing: normal values in the Australian Population. Int J Immunopharmacol 1995;17:629-34.
12. + T-cell-mediated suppression or HIV replication in the first year of life: association with lower viral load and favorable early survival. AIDS 1997;11:F9-13.
13. + T cell anti-HIV activity. Clin Immunol Immunopathol 1994;73;80-7.
14. + T cell responses associated with control or viremia. Science 1997;278:1447-50.
15. + T cells and this effect overrides its ability to stimulate virus expression. Proc Natl Acad Sci USA 1995;92:10985-9.
16. Ogg GS, Yin X, Bonhoeffer S, et al. Quantitation of HIV-1 specific cytotoxic T-lymphocytes and plasma load of viral RNA. Science 1998;279:2103-6.
17. Tenner-Racz K, Stellbrink HJ, van Lunzen J, et al. The unenlarged lymph nodes of HIV-1 infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapy. J Exp Med 1998;187:949-59.
18. + cells. Immunol Today 1996;17:217-24.
19. Joly P, Guillon JM, Mayaud C, et al. Cell-mediated suppression of HIV-specific cytotoxic T lymphocytes. J Immunol 1989;143:2193-201.
20. + T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol 1993;69:106-16.
21. Toso JF, Chen CH, Mohr JR, et al. Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication. J Infect Dis 1995;172:964-73.
22. + cell suppression of HIV replication. J Immunol 1997;159:5123-31.
23. + T lymphocyte-mediated nonlytic suppression of autologous and heterologous primary human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 1997;13:685-93.
24. Bisset LR, Rothen M, Joller-Jemelka HI, Dubs RW, Grob PJ, Opravil M. Change in circulating level of the chemokines macrophage inflammatory proteins 1α and 1β, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. AIDS 1997;11:485-91.
25. Baier M, Werner A, Bannert N, Metzner K, Kurth R. HIV suppression by interleukin-16 [letter]. Nature 1995;378:563.
26. + T cells. Science 1995;270:1811-5.
27. + T-cell derived factor(s), but not β-chemokines RANTES, MIP-1α, and MIP-1β, suppress HIV-1 replication in monocyte/macrophages. Proc Natl Acad Sci USA 1996;93:15341-5.
28. Aukrust P, Müller F, Frøland SS. Circulating levels of RANTES in human immunodeficiency virus types 1 infection: effect or potent antiretroviral therapy. J Infect Dis 1998;177:1091-6.
29. + T cells in HIV-1 infected individuals. Intervirology 1997;40:263-70.
30. Diszicwicz J, Jessen H, Finzi D, Sciliciano RF, Lori F. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor. Lancet 1998;352:199-200.